Orforglipron (also known as Foundayo) is one of the most promising drugs in the GLP-1 space, notably as only the second oral GLP-1 option for obesity. Unlike injectable treatments, it does not require refrigeration and is easier to scale for widespread use.<br>Dave highlights the ongoing questions that linger about the drugs approval as it relates to liver safety.

Foundayo GLP-1 Pill: FDA Needs More Data

On The Pen GLP-1 News

What if I told you that one of the biggest risks to the GLP-1 category right now isn't access? It's how the next generation of these drugs behaves at scale and specifically how small molecule GLP-1s interact with the liver. When you move from peptide based GLP-1s to small molecule drugs, you introduce a different risk profile.

And the part that I think that many people gloss over when it comes to this is that if that signal actually shows up in the real world, it doesn't stay contained to that one drug. They're not going to say that was a small molecule issue. They're going to say that's a GLP-1 problem. And that's why what the FDA is doing right now matters a ton if you're paying attention to this space. Welcome back to On The Pen.

Welcome to the On The Pen podcast with your host, Dave Knapp. Welcome back to the On The Pen podcast. I'm your host, Dave Knapp, man on the Manjaro. That's why I'm here. You are on the pen. We go V, sex, Saxenda, Victoza, Trulicity, Mounjaro, ZepBound, Foundeo.

That pen or now pill is what we talk about each and every week here at On The Pen because we want to empower you to have more competent and confident conversations. With your doctor. So as you're jumping in here, if you're new and you're listening on the podcast, drop us a five star rating and review. If you're listening on YouTube, hit the thumbs up button, subscribe down below, hit the bell for notifications. And in the description of this video, there's a hype button. Give this a hype because it's going to help push this video out to other people who need it.

Foundayo GLP-1 Pill: FDA Needs More Data

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Foundayo GLP-1 Pill: FDA Needs More Data

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.